In crisis or thinking about suicide? Call or text 988 in the US for the Suicide and Crisis Lifeline, available 24 hours a day. If someone is in immediate danger, call 911.

shrinkopedia.

Part of The Shrink Network

Crisis help
Share this page
Treatment

SNRIs

also known as serotonin-norepinephrine reuptake inhibitors

Medically reviewed by the Shrinkopedia editorial team, led by Shariq Refai, MD, MBA, FAPA.

7 min read · 1,563 words

  • Medically reviewed . Reviewed by a board-certified psychiatrist before publication.
  • Sourced from primary literature . DSM-5-TR, NICE, the American Psychiatric Association, the NIMH, Cochrane, peer-reviewed research.
  • Dated and kept current . Every entry shows when it was published, reviewed, and last updated.
  • Honest about uncertainty . Each entry carries an evidence-strength rating and a "what we know and what we don't" section.
  • Independent . No advertising, no affiliate revenue, no sponsored content.
Quick answer

SNRIs, or serotonin-norepinephrine reuptake inhibitors, are a class of antidepressant medication that acts on two brain chemicals, serotonin and norepinephrine. They're used for depression and several anxiety disorders, and some are also used for certain chronic pain conditions. Decisions about them belong with a prescriber.

Prefer the quick definition? Read this term on Shrinktionary →

Definition

SNRIs are a class of medication used to treat depression and a range of anxiety conditions. They increase the availability of two neurotransmitters, serotonin and norepinephrine, by blocking the reabsorption of both back into nerve cells.

That second action on norepinephrine is the main difference from SSRIs, which act mainly on serotonin. SNRIs are an established option, sometimes chosen first and sometimes considered when an SSRI hasn't worked well enough. They're often used alongside therapy rather than in place of it.

### The SNRIs at a glance

SNRIBrandTypical adult doseNE effectNotable features
venlafaxine XREffexor XR75-225 mgdose-dependent (NE kicks in above ~150 mg)monitor BP; substantial discontinuation syndrome
desvenlafaxinePristiq50 mg (usually)modestactive metabolite of venlafaxine; simpler PK, no dose titration required
duloxetineCymbalta60 mg (30-120)present at therapeutic dosesapproved for fibromyalgia, chronic musculoskeletal pain, diabetic neuropathy
levomilnacipranFetzima40-120 mgmore NE than most SNRIslimited comparative data; used less often
milnacipranSavella100-200 mgstrong NEUS: approved only for fibromyalgia (not depression)

What it looks like

  • A person who didn't get enough benefit from an SSRI is switched to an SNRI as a next step.
  • A prescriber chooses an SNRI first because it also addresses a coexisting chronic pain problem.
  • Blood pressure is checked at a follow-up visit after a dose increase.
  • When it's time to stop, the medication is tapered slowly rather than stopped at once.

What people often confuse this with

SSRIs. SNRIs and SSRIs overlap a lot, but they aren't the same. SNRIs add an effect on norepinephrine, which can shift both the benefits and the side-effect profile, including the possibility of raised blood pressure at higher doses.

A painkiller. Some SNRIs are used for certain chronic pain conditions, but they aren't painkillers in the everyday sense. They work over weeks and act on the nervous system rather than blocking pain directly the way an over-the-counter analgesic does.

An addictive drug. SNRIs aren't addictive in the usual sense of that word. Stopping abruptly can cause discontinuation symptoms, which is a separate issue and is why changes are made gradually.

Reality check

Myth: SNRIs work faster than SSRIs.

The timeline is similar. SNRIs also take several weeks to reach their full therapeutic effect, often longer than side effects take to appear. A slow start isn't a sign the medication has failed.

Myth: SNRIs are addictive.

They aren't addictive in the colloquial sense. There's a separate safety point: the FDA carries a boxed warning about a small increased risk of suicidal thoughts in people under 25, especially early in treatment, which is why close monitoring in the first weeks matters. Discontinuation symptoms can be pronounced with shorter-acting agents, so tapering with a prescriber matters too.

Myth: An SNRI must be stronger than an SSRI because it acts on two chemicals.

Acting on two neurotransmitters doesn't simply mean "stronger." It means a somewhat different profile of effects, which can suit some people and situations better, and SSRIs better in others. Which one fits depends on the person, not on a ranking.

What research says

SNRIs are well studied, and the evidence supporting them is strong.

  • Depression. SNRIs are an evidence-based medication option, supported by randomized trials and clinical guidelines.
  • Anxiety disorders. They're used for generalized anxiety, panic, and social anxiety disorder, with good supporting evidence.
  • As a next step. SNRIs are often considered when a first SSRI hasn't worked well enough.
  • Chronic pain. Some SNRIs, notably duloxetine, are also used for certain chronic pain conditions.
  • Side effects. The profile overlaps with SSRIs and can include raised blood pressure at higher doses, particularly with venlafaxine.

Guidelines from NICE, and FDA labeling, support SNRIs across these uses, often alongside therapy such as CBT.

What we know and what we don't know

What we know

  • SNRIs are an evidence-based medication for depression and several anxiety disorders, and some are used for certain chronic pain conditions.
  • They act on both serotonin and norepinephrine, take several weeks for the full effect, and can raise blood pressure at higher doses.
  • They aren't addictive in the usual sense, but discontinuation symptoms can be pronounced, so they're tapered with a prescriber.

What we don't know

  • We can't reliably predict who will do better on an SNRI than an SSRI, so finding the right fit can take some adjustment.
  • The biology of why they help isn't fully explained.
  • The practical advantage of acting on two neurotransmitters, and for whom it matters most, is still being clarified.

Questions people ask

How do SNRIs differ from SSRIs?

SNRIs block reuptake of both serotonin and norepinephrine; SSRIs block only serotonin reuptake. Clinically, SNRIs are often used for depression and generalized anxiety, and are considered first-line for some chronic pain conditions. Side-effect profiles overlap with SSRIs but include some differences (more effect on blood pressure with venlafaxine at higher doses). PsychiatryRx has an interactive guide to how SNRIs work.

Which SNRI is best?

Venlafaxine, duloxetine, and desvenlafaxine are the most commonly used. Duloxetine has an approval for chronic pain conditions. Venlafaxine has more discontinuation issues than duloxetine because of its shorter half-life. Individual response varies; no single SNRI is universally best.

Do SNRIs cause weight gain?

Less consistently than some SSRIs. Some weight gain over time is possible with any antidepressant, but SNRIs are often relatively weight-neutral compared to some other options.

What are the withdrawal effects?

Discontinuation syndrome can be prominent, particularly with venlafaxine because of its short half-life. Dizziness, brain zaps, flu-like symptoms, mood changes. Tapering over weeks under a prescriber's guidance minimizes it.

Are SNRIs safe long-term?

Yes, for most people. Long-term use is common and generally well tolerated. Blood pressure monitoring is worthwhile with higher doses of venlafaxine.

What it involves

Treatment with an SNRI usually involves:

  • a prescriber assessing whether medication fits, and which one to try
  • starting at a low dose, often increased gradually
  • a wait of several weeks for the full therapeutic effect, on a similar timeline to SSRIs
  • early check-ins to monitor side effects and response
  • monitoring of blood pressure, particularly at higher doses
  • any changes, including stopping, made gradually and with the prescriber

Common SNRIs include venlafaxine, desvenlafaxine, duloxetine, and levomilnacipran. Some, such as duloxetine, are also used for certain chronic pain conditions. This entry is an overview. For drug-by-drug detail and dosing, see the plain-language guides at PsychiatryRx.org.

Medications in this class

Class receptor mechanism. Dual reuptake inhibition at SERT and NET. NET affinity increases with dose in venlafaxine (mostly serotonergic at low dose, noradrenergic at higher doses).

Class monitoring. Same as SSRIs plus: blood pressure (dose-related HTN, especially venlafaxine > 150 mg/day), heart rate, sweating, urinary retention.

Venlafaxine

Receptor mechanism. SERT >> NET at doses < 150 mg/day; balanced at ≥ 225 mg/day; minimal DAT activity at very high doses.
Typical dosing. ER: 37.5-75 mg/day starting, titrated to 75-225 mg/day (up to 375 mg/day). Short half-life carries significant discontinuation syndrome risk; taper slowly.
Safety monitoring. BP at baseline and 2, 4, 8 weeks and periodically; ECG if cardiac risk; standard SSRI-class monitoring.
Sources. FDA label (Effexor XR); NICE NG222.

Desvenlafaxine

Receptor mechanism. Active metabolite of venlafaxine; more balanced SERT/NET profile.
Typical dosing. 50 mg/day (no titration needed for efficacy at 50 mg); up to 100 mg/day.
Safety monitoring. Same as venlafaxine.
Sources. FDA label (Pristiq).

Duloxetine

Receptor mechanism. Balanced SERT/NET inhibition throughout dose range.
Typical dosing. 30 mg/day for 1 week then 60 mg/day; MDD max 120 mg/day; also FDA-approved for GAD, diabetic neuropathy, fibromyalgia, chronic musculoskeletal pain.
Safety monitoring. BP; LFTs (avoid with heavy alcohol use or liver disease); standard class monitoring.
Sources. FDA label (Cymbalta); APA MDD guideline.

Levomilnacipran

Receptor mechanism. NET-preferring SNRI (≈2× NET vs SERT affinity).
Typical dosing. 20 mg/day for 2 days then 40 mg/day; up to 120 mg/day.
Safety monitoring. BP and HR (more NE-driven); standard class.
Sources. FDA label (Fetzima).
Shared safety themes.
  • Pregnancy and breastfeeding. Every entry should link to condition-specific perinatal considerations and reference LactMed/NICE/APA perinatal guidance.
  • Drug interactions. SSRIs/SNRIs + MAOIs (14-day washout, 5 weeks for fluoxetine); lithium + NSAIDs/ACEi/thiazides; carbamazepine broad CYP induction; clozapine + fluvoxamine, ciprofloxacin.
  • Discontinuation. Taper SSRIs, SNRIs, benzodiazepines, and antipsychotics gradually. Fastest tapers (paroxetine, venlafaxine, short-acting benzos) carry the most discontinuation symptoms.
  • Metabolic monitoring standard. Per the ADA/APA consensus, still the standard framework in 2026: baseline, 4, 8, 12 weeks, then quarterly: weight/BMI, waist. Baseline, 3 months, then annually: fasting glucose or HbA1c, fasting lipids, BP.
  • QTc considerations. Baseline ECG for citalopram > 20 mg (age > 60), ziprasidone, IV haloperidol, thioridazine, and any combination of QT-prolonging agents.

Sources

  1. U.S. Food and Drug Administration (FDA). SNRI labeling and the boxed warning on suicidal thoughts in young people.
  2. National Institute for Health and Care Excellence (NICE). Guidance on depression and anxiety disorders.
  3. Clinical practice guidelines and randomized trials on SNRIs for depression and anxiety disorders.
  4. Research literature on SNRIs in certain chronic pain conditions.
  5. FDA prescribing information (label) for each drug, accessed via DailyMed.
  6. APA Practice Guidelines (Schizophrenia 3rd ed.; MDD; Bipolar Disorder; OCD).
  7. NICE Guidelines: NG222 (Depression 2022), CG185 (Bipolar 2014, updated), CG178 (Psychosis and schizophrenia 2014, updated), NG215 (Medicines associated with dependence).
  8. ADA/APA Consensus on Antipsychotic Drugs and Obesity/Diabetes (2004, still foundational; updates via ISBD/EPA metabolic monitoring statements).
  9. Carolan A, et al. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophrenia Bulletin. 2025;51(5):1193-1203.
  10. FDA Drug Safety Communication: Clozapine REMS elimination (February 24, 2025).
  11. AAPP Clozapine in Practice guideline (2025 updates).
  12. International Society for Bipolar Disorders (ISBD) lithium and mood-stabilizer consensus statements.
  13. APA/ASKP Consensus on Ketamine and Esketamine (2017 base; 2023-2025 updates).
  14. Beers Criteria (AGS 2023) and STOPP/START v3 (2023) for prescribing in older adults.
  15. Cochrane systematic reviews for individual class efficacy and safety.

Read how Shrinkopedia builds and reviews its content.

How to cite this page

Short
SNRIs. Shrinkopedia, medically reviewed by Shariq Refai, MD, MBA. https://shrinkopedia.com/treatments/snris/
APA
Shrinkopedia. (2026, June 8). SNRIs. Medically reviewed by Shariq Refai, MD, MBA. https://shrinkopedia.com/treatments/snris/
MLA
"SNRIs." Shrinkopedia, 8 June 2026, https://shrinkopedia.com/treatments/snris/.

Click a citation to select it.

Medical disclaimer

Shrinkopedia is for education, not medical advice. It can't tell you whether an SNRI is right for you, and it isn't a substitute for care from a licensed clinician. Medication decisions, including starting, changing, or stopping, belong with a prescriber who knows your situation.

If you're in crisis or thinking about harming yourself, call or text 988 in the US to reach the Suicide and Crisis Lifeline, or call 911.

See where this fits in the Atlas: how your mind works →

The Knowledge Path

Walk the connection from this entry outward.

  1. 1 TREATMENT SNRIs (current)
  2. 2 CONDITION Depression vs burnout
  3. 3 SYMPTOM Anhedonia
  4. 4 MEDICATION SSRIs explained
  5. 5 CARE Depression care at shrinkMD

The Knowledge Path is a curated walk. Every step is one decision away from the next.

Your next step in The Shrink Network

You are here: Shrinkopedia, the concept layer of The Shrink Network.

Understand the idea here first, then follow it to the property that takes it further.

Read a related treatment →

Want to understand more first?

Disclosure: shrinkMD is the clinical care practice within The Shrink Network, the same network that publishes Shrinkopedia. Shrinkopedia takes no referral or affiliate commission for care.

Share this page